"Breakthrough Treatment Offers Hope for Aggressive Brain Tumors"
Originally Published 2 years ago — by ScienceAlert
Scientists have discovered a potential breakthrough in the treatment of diffuse midline gliomas (DMGs), a deep-rooted and aggressive form of brain cancer that often develops in childhood. A drug called ONC201 has shown promise in clinical trials, with patients experiencing a median overall survival time of 22 months compared to 11-15 months without treatment. ONC201 targets neural pathways for dopamine and has the ability to pass through the blood-brain barrier. The drug affects the mitochondria of cancer cells, reversing epigenetic signals associated with tumor growth. Further clinical trials are underway to explore the effectiveness of ONC201 in combination with other treatments.